Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386555 | PMC |
| http://dx.doi.org/10.3389/fpls.2022.994380 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intelligent biology and medicine: Accelerating innovative computational approaches.
Comput Struct Biotechnol J
November 2024
Center for Precision Health, McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
In this editorial, we summarize the 2023 International Conference on Intelligent Biology and Medicine (ICIBM 2023) conference which was held on July 16-19, 2023 in Tampa, Florida, USA. We then briefly describe the nine research articles included in this special issue. ICIBM 2023 scientific program included four tutorials and workshops, four keynote lectures, four eminent scholars' presentations, 11 concurrent scientific sessions, and a poster session.
View Article and Find Full Text PDFLecanemab approval in EU: what should we be ready for?- the EANM perspective.
Eur J Nucl Med Mol Imaging
January 2025
Department of Radiology and Nuclear Medicine, Ghent University Hospital, Ghent, Belgium.
PET molecular imaging-based prevention for brain aging.
Eur J Nucl Med Mol Imaging
January 2025
Department of Nuclear Medicine and PET Center, The Second Affiliated Hospital of Zhejiang, University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, China.
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.
Nat Cancer
January 2025
Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Immune checkpoint inhibitors can lead to 'exceptional', durable responses in a subset of persons. However, the molecular basis of exceptional response (ER) to immunotherapy in metastatic clear cell renal cell carcinoma (mccRCC) has not been well characterized. Here we analyzed pretherapy genomic and transcriptomic data in treatment-naive persons with mccRCC treated with standard-of-care immunotherapies: (1) combination of programmed cell death protein and ligand 1 (PD1/PDL1) and cytotoxic T lymphocyte-associated protein 4 inhibitors (IO/IO) or (2) combination of PD1/PDL1 and vascular endothelial growth factor (VEGF) receptor inhibitors (IO/VEGF).
View Article and Find Full Text PDFSuppression of inflammatory macrophages is a potential strategy to improve rotator cuff healing and has shown promise in preclinical models.
Arthroscopy
January 2025
HSS Sports Medicine Institute, Hospital for Special Surgery; Orthopaedic Soft Tissue Research Program, Hospital for Special Surgery Research Institute. Electronic address:
The pathophysiology of rotator cuff disease is complex, involving intrinsic and extrinsic factors that contribute to mechanical alterations, inflammation, apoptosis, and neovascularization. These changes result in structural and cellular disruptions, including inflammatory cell infiltration and collagen disorganization. Macrophages have recently gained attention as critical mediators of tissue repair and regeneration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!